• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deals search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • People moves
    • Analysis
    • In Profile
    • Q&A
    • Videos
    • Comment
  •  
    Analysis
    • In Profile
    • Fundraising
    • Q&A
    • Comment
    • Videos
    • Podcast
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
Unquote
  • LPs

Q&A - John Gripton, Managing director, Capital Dynamics

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

Given the downturn in the markets, do you as an LP do anything differently now? What advice would you give to a first time investor?

We would not do a lot differently now, as I believe private equity is a long-term asset class where you can't opt in or out of various sectors based on where the market is. Capital Dynamics keeps a broad, diversified portfolio and while there may be some more exposure to distressed assets now, we would not make a drastic shift in strategy. We always look at the best managers for each area of private equity and their returns over an average of 10 years or so, not on a year-by-year basis. For a first-time investor, I would say that now more than ever, they need the support of specialist managers or advisers in the market. In the current economic environment it is a whole different ball game now and a lot more work is required in identifying which managers to support. With performance in recent years it's not going to be as easy as it was before, as now investors will have to think more about portfolio and risk management strategies. They must carefully consider how much they want to commit now and if they will be able to sustain this amount going forward.

What would you say is the biggest change in terms of how a GP treats its LPs now?

I would say that with better GPs, those that are looking to make long-term relationships with LPs, very little has actually changed. Those that were more opportunistic in the past will not be able to command the terms they did previously. Things that will change are not necessarily the management fees or carried interest, but rather there will be more of a focus on areas such as key-man clause and transaction fee issues. LPs have been frustrated to a degree in the past with key-man clauses that have been too weak and with the lack of transparency on transaction fees. Investors will also be able to press more for the information that is necessary for them to do their jobs.

What is more relevant when assessing the merit of a GP, their track record or the current underlying portfolio?

Both are incredibly important, but for different reasons. The track record looks at managers' ability to generate returns through different economic cycles. You can't rely on this to predict future performance, but it does give a measure of the GP's experience over differing cycles. If a manager has one buyout fund that didn't make the best returns, this is no reason not to invest with them. Current underlying portfolio is now more important than ever, in the sense that you have to look at the health of each individual company. This includes the company's performance, how it is structured in terms of debt, when it will need to be refinanced, etc. Capital Dynamics has always looked at this, but we are now doing it more carefully than before and with a different emphasis. Which members of the GP's team are really involved in the current portfolio? Will these same people be there in the future? This will be particularly important when the debt of these companies matures in 2013 and a great deal of work is required.

What is the best indication of the true skill of a GP - cash in vs out over the last five years, or current performance (realised and unrealised)?

I think that cash in vs out in the last five years is important, especially when merged with managers' track records. If a GP didn't divest between 2006 and 2007, then a big question to the manager would be, why? Were they investing more than divesting? Have they overpaid for their investments? We are less likely to invest with a GP that hasn't maintained pricing discipline consistently. But there is never a time where our due diligence doesn't give rise to some concern. The question is whether the concern is sufficient to stop us from investing. We must be able to address the issue or get comfortable with it. With current performance, we would again look at the health of the underlying companies. Are the companies profitable and performing to plan - to the original budget as well as this year's? If there are problems here, then we would have to question and reassess the value of unrealised performance. However, if companies are valued at zero, this is not to say that they will not be of value in two to three years time. The unrealised part of a GP's performance is also crucial in terms of workload and understanding how well the manager will be able to cope with it in the future.

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • LPs
  • UK / Ireland
  • DACH
  • Nordics
  • France
  • Southern Europe
  • CEE
  • Benelux

More on LPs

EU foreign subsidies regulations
EU FSR could impact PE fundraising with potential rise in ‘clean funds’

FSR could lead GPs to create funds without foreign LPs; red tape around sovereign wealth funds likely

  • Regulation
  • 01 September 2023
Tim Ickenroth of Golding Capital Partners
Golding adds insurance expertise with hire for institutional clients team

Tim Ickenroth joins as director with prior experience at BNP Paribas and UniCredit

  • People
  • 11 August 2023
The Unquote Private Equity Podcast
Unquote Private Equity Podcast: PE perspectives from Berlin

Unquote’s Min Ho and Rachel Lewis digest the key takeaways from this year’s SupeReturn

  • Fundraising
  • 23 June 2023
European Union flags
EU Foreign Subsidies rules hold specific challenges for PE

Sovereign wealth funds and pension funds commitments may trigger EC attention under new EU foreign subsidies regulation

  • Regulation
  • 22 June 2023

Latest News

Fund closes in US dollars
  • Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote

  • 05 September 2023
Clinical trials and biotechnology
  • Buyouts
Permira to take Ergomed private for GBP 703m

Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO

  • 04 September 2023
Public sector software
  • Exits
Partners Group to release IMs for Civica sale in mid-September

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • 04 September 2023
EMEA Public to Private M&A
  • Investments
Change of mind: Sponsors take to de-listing their own assets

EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater

  • 04 September 2023
Back to Top
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013